These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17492913)

  • 1. Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study.
    Nishikawa T; Hayashi T; Koga I; Uchida Y
    Psychiatry; 2007; 70(1):68-79. PubMed ID: 17492913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal symptoms after long-term treatment with low-potency neuroleptics.
    Chouinard G; Bradwejn J; Annable L; Jones BD; Ross-Chouinard A
    J Clin Psychiatry; 1984 Dec; 45(12):500-2. PubMed ID: 6150030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation trial on the efficacy of neuroleptics on the outcome of schizophrenia].
    Dollfus S; Petit M
    Encephale; 1991; 17(4):247-53. PubMed ID: 1683625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
    Steiner S
    Psychiatr Clin (Basel); 1980; 13(3-4):165-78. PubMed ID: 7244281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound insomnia in neuroleptic drug withdrawal neurophysiologic characteristics.
    van Sweden B
    Pharmacopsychiatry; 1987 May; 20(3):116-9. PubMed ID: 2885865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission in schizophrenia: analysis in a naturalistic setting.
    Eberhard J; Levander S; Lindström E
    Compr Psychiatry; 2009; 50(3):200-8. PubMed ID: 19374962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroleptic low-dose long-term strategy and intermittent therapy strategy in chronic schizophrenia--a critical review].
    Hofmann P; Melisch B; Zapotoczky HG; Kulhanek F
    Fortschr Neurol Psychiatr; 1993 Jun; 61(6):195-200. PubMed ID: 8101177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The risk of neuroleptic discontinuation in schizophrenia].
    Jarema M
    Psychiatr Pol; 1999; 33(1):69-81. PubMed ID: 10786216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Late extrapyramidal hyperkinesis and neuroleptic withdrawal dyskinesia. Practical problems].
    Hoffmann C; Faust V
    Fortschr Med; 1983 Mar; 101(11):470-6. PubMed ID: 6133824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study.
    Bachmann S; Bottmer C; Schroder J
    Psychopathology; 2008; 41(2):115-23. PubMed ID: 18059113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Discontinuation of neuroleptic treatment in patients with schizophrenia].
    Alagille M; Blondiaux I; Ginestet D
    Encephale; 1990; 16(2):125-31. PubMed ID: 1972052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of neuroleptics in community-dwelling individuals with mental retardation and mental illness.
    Pary RJ
    Am J Ment Retard; 1995 Sep; 100(2):207-12. PubMed ID: 8527116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S; Kornreich C; Choubani Z; Gourevitch R
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
    Cassinotti A; Actis GC; Duca P; Massari A; Colombo E; Gai E; Annese V; D'Albasio G; Manes G; Travis S; Porro GB; Ardizzone S
    Am J Gastroenterol; 2009 Nov; 104(11):2760-7. PubMed ID: 19623172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing].
    Mercier C; Bret P; Bret MC; Queuille E
    Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.